

Harriet M Kluger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4757133/publications.pdf>

Version: 2024-02-01

193
papers

17,763
citations

30070

54
h-index

14759

127
g-index

195
all docs

195
docs citations

195
times ranked

23332
citing authors

#	ARTICLE	IF	CITATIONS
1	Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. <i>Annals of Surgical Oncology</i> , 2022, 29, 415-424.	1.5	4
2	Central Nervous System Metastases. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 161-188.	2.2	10
3	CheckMate-067: Raising the Bar for the Next Decade in Oncology. <i>Journal of Clinical Oncology</i> , 2022, 40, 111-113.	1.6	8
4	Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. <i>BMJ Open Ophthalmology</i> , 2022, 7, e000889.	1.6	10
5	TCR-sequencing in cancer and autoimmunity: barcodes and beyond. <i>Trends in Immunology</i> , 2022, 43, 180-194.	6.8	20
6	Emerging Studies of Melanoma Brain Metastasis. <i>Current Oncology Reports</i> , 2022, 24, 585-594.	4.0	5
7	Reply to T. Olivier et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200209.	1.6	0
8	Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. , 2022, 10, e004421.		19
9	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	2.8	25
10	Inhibition of renalase drives tumour rejection by promoting T cell activation. <i>European Journal of Cancer</i> , 2022, 165, 81-96.	2.8	2
11	Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	6
12	Clinical predictors of longer survival in patients with BRAF ^{V600} -mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9555-9555.	1.6	0
13	Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9524-9524.	1.6	2
14	Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. <i>JAMA Network Open</i> , 2022, 5, e2219535.	5.9	6
15	Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. <i>Journal of Neuro-Oncology</i> , 2021, 152, 15-25.	2.9	15
16	Primary Treatment Selection for Clinically Nodeâ€Negative Merkel Cell Carcinoma of the Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 1214-1221.	1.9	4
17	Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. <i>PLoS ONE</i> , 2021, 16, e0246764.	2.5	19
18	Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. <i>Scientific Reports</i> , 2021, 11, 2809.	3.3	20

#	ARTICLE	IF	CITATIONS
19	Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	48
20	Agonistic CD40 Antibodies in Cancer Treatment. <i>Cancers</i> , 2021, 13, 1302.	3.7	50
21	Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. <i>Cancers</i> , 2021, 13, 1049.	3.7	9
22	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	5.5	25
23	Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. <i>Npj Precision Oncology</i> , 2021, 5, 45.	5.4	11
24	A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2676-TPS2676.	1.6	4
25	Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. , 2021, 9, e002535.		13
26	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. <i>Science</i> , 2021, 372, .	12.6	114
27	A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Nonâ€“Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2021, 27, 4757-4767.	7.0	44
28	Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 495-501.	1.3	11
29	Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab. , 2021, , .		0
30	Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. <i>European Journal of Cancer</i> , 2021, 151, 25-34.	2.8	59
31	Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. <i>American Journal of Clinical Pathology</i> , 2021, 156, 550-558.	0.7	0
32	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	1.6	145
33	Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2021, 154, 197-203.	2.9	10
34	ASO Visual Abstract: Merkel Cell Carcinomaâ€“Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. <i>Annals of Surgical Oncology</i> , 2021, 28, 736-737.	1.5	2
35	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. <i>Clinical Cancer Research</i> , 2021, 27, 1987-1996.	7.0	38
36	Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. <i>Oncolmmunology</i> , 2021, 10, 1864909.	4.6	18

#	ARTICLE	IF	CITATIONS
37	KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. <i>Nature</i> , 2021, 598, 682-687.	27.8	117
38	Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. , 2021, 4, .		1
39	Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. , 2021, 4, .		0
40	Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases. , 2021, 9, e002684.		8
41	Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death. <i>Clinical Cancer Research</i> , 2020, 26, 1126-1134.	7.0	78
42	PLEKHA5 regulates tumor growth in metastatic melanoma. <i>Cancer</i> , 2020, 126, 1016-1030.	4.1	12
43	19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA. <i>Neuro-Oncology Advances</i> , 2020, 2, ii3-ii3.	0.7	0
44	Targeting Innate Immunity to Treat Cancer. <i>Cancers</i> , 2020, 12, 2723.	3.7	1
45	[¹¹ C]Methionine and [¹¹ C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. <i>Molecular Imaging</i> , 2020, 19, 153601212096866.	1.4	12
46	P865â€¦Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies â€“ independent review committee data update. , 2020, , .		3
47	Regulation of eIF2 γ by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2466-2477.	0.7	13
48	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 655-663.	10.7	335
49	Neoadjuvant antiâ€“programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naïve patients: A case series. <i>JAAD Case Reports</i> , 2020, 6, 628-633.	0.8	8
50	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 527-541.	3.3	36
51	Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. , 2020, 8, e000341.		48
52	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
53	High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis. <i>American Journal of Surgical Pathology</i> , 2020, 44, 582-593.	3.7	24
54	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173.	9.4	158

#	ARTICLE	IF	CITATIONS
55	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.. Journal of Clinical Oncology, 2020, 38, 10006-10006.	1.6	32
56	A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.. Journal of Clinical Oncology, 2020, 38, 3094-3094.	1.6	5
57	FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2020, 38, 5007-5007.	1.6	28
58	A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. Journal of Clinical Oncology, 2020, 38, TPS3158-TPS3158.	1.6	2
59	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2020, , 1421-1454.		0
60	Cardiac Biventricular Metastasis From Renal Cell Carcinoma. Cureus, 2020, 12, e10870.	0.5	0
61	Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. , 2020, 3, .		0
62	Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy. , 2019, 7, 200.		23
63	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. , 2019, 7, 196.		62
64	Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. , 2019, 7, 194.		47
65	Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study. Clinical Genitourinary Cancer, 2019, 17, e1163-e1170.	1.9	36
66	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibitionâ€”A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology, 2019, 37, 3350-3358.	1.6	52
67	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. , 2019, 7, 254.		14
68	Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1113-1118.	0.8	14
69	High-Plex Predictive Marker Discovery for Melanoma Immunotherapyâ€”Treated Patients Using Digital Spatial Profiling. Clinical Cancer Research, 2019, 25, 5503-5512.	7.0	117
70	B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. , 2019, 7, 153.		58
71	Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. Cell Reports, 2019, 27, 1277-1292.e7.	6.4	49
72	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R β -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discovery, 2019, 9, 711-721.	9.4	180

#	ARTICLE	IF	CITATIONS
73	Reply to A. Shinde et al. Journal of Clinical Oncology, 2019, 37, 1031-1032.	1.6	0
74	Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology, 2019, 126, 1058-1062.	5.2	43
75	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal of Clinical Oncology, 2019, 37, 52-60.	1.6	218
76	Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal of the American Academy of Dermatology, 2019, 80, 990-997.	1.2	130
77	Complications associated with immunotherapy for brain metastases. Current Opinion in Neurology, 2019, 32, 907-916.	3.6	27
78	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 2442-2449.	7.0	106
79	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq1 1 0.784314 rgBT /Overlock I including anti-PD-1.. Journal of Clinical Oncology, 2019, 37, 2518-2518.	1.6	71
80	Baseline tumor-immune signatures associated with response to bempedaldesleukin (NKTR-214) and nivolumab.. Journal of Clinical Oncology, 2019, 37, 2623-2623.	1.6	20
81	United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon- γ 2b for resected high-risk melanoma.. Journal of Clinical Oncology, 2019, 37, 9504-9504.	1.6	15
82	Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.. Journal of Clinical Oncology, 2019, 37, 9533-9533.	1.6	2
83	Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity.. Journal of Clinical Oncology, 2019, 37, e14114-e14114.	1.6	4
84	Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti- α PD-1/PD-L1 agents: Phase 2 LEAP-004 study.. Journal of Clinical Oncology, 2019, 37, TPS9594-TPS9594.	1.6	1
85	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2019, , 1-34.		0
86	Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.. Journal of Clinical Oncology, 2019, 37, 2066-2066.	1.6	0
87	Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clinical Cancer Research, 2018, 24, 217-223.	7.0	23
88	A Serum Protein Signature Associated with Outcome after Anti- α PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research, 2018, 6, 79-86.	3.4	61
89	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2018, 36, 391-398.	1.6	156
90	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35

#	ARTICLE	IF	CITATIONS
91	Genomic Heterogeneity and the Small Renal Mass. <i>Clinical Cancer Research</i> , 2018, 24, 4137-4144.	7.0	11
92	Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. <i>Diabetes</i> , 2018, 67, 1471-1480.	0.6	386
93	Anti-PD-1 Therapy-Associated Perforating Colitis. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-3.	0.3	24
94	Early B cell changes predict autoimmunity following combination immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 715-720.	8.2	298
95	Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2009-2009.	1.6	33
96	Safety and feasibility of immuno-cryotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 34-34.	1.6	0
97	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	6.4	59
98	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	7.0	117
99	Comparing available criteria for measuring brain metastasis response to immunotherapy. <i>Journal of Neuro-Oncology</i> , 2017, 132, 479-485.	2.9	39
100	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.6	58
101	Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
102	SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth. <i>Journal of Clinical Investigation</i> , 2017, 128, 517-530.	8.2	36
103	Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2545-2545.	1.6	19
104	Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3007-3007.	1.6	15
105	Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3045-3045.	1.6	8
106	Microvessel density as a prognostic marker in high-risk renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4565-4565.	1.6	4
107	A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9500-9500.	1.6	56
108	A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14040-e14040.	1.6	12

#	ARTICLE	IF	CITATIONS
109	MET Inhibition in Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 1205-1214.	2.5	23
110	Systemic Immunotherapy for the Treatment of Brain Metastases. <i>Frontiers in Oncology</i> , 2016, 6, 49.	2.8	66
111	Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. <i>Cancer</i> , 2016, 122, 3051-3058.	4.1	182
112	Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism. <i>Cancer Research</i> , 2016, 76, 3884-3894.	0.9	41
113	Evolving Immunotherapy Approaches for Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 57.	4.0	24
114	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	3.3	102
115	The Treatment of Melanoma Brain Metastases. <i>Current Oncology Reports</i> , 2016, 18, 73.	4.0	16
116	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 976-983.	10.7	846
117	Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1193-1200.	2.3	8
118	Melanoma: Clinical Presentations. <i>Cancer Treatment and Research</i> , 2016, 167, 107-129.	0.5	59
119	Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. <i>Cancer Immunology Research</i> , 2016, 4, 481-487.	3.4	49
120	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2170-2175.	7.1	102
121	Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. <i>Cancer Immunology Research</i> , 2016, 4, 179-182.	3.4	115
122	Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?. <i>Journal of Neurosurgery</i> , 2016, 125, 17-23.	1.6	192
123	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 374-382.	7.0	38
124	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. <i>JCI Insight</i> , 2016, 1, e88955.	5.0	111
125	Autologous genetically engineered NY-ESO-1 ^{c259} T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3101-TPS3101.	1.6	3
126	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 509-509.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. <i>Journal of Radiosurgery and SBRT</i> , 2016, 4, 97-106.	0.2	1
128	Clinical trials in melanoma patients with brain metastases. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 741-743.	3.3	10
129	MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	6
130	The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. <i>Science Signaling</i> , 2015, 8, ra124.	3.6	46
131	Role of Chitinase 3-like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis. <i>Cancer Research</i> , 2015, 75, 487-496.	0.9	71
132	PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. <i>Clinical Cancer Research</i> , 2015, 21, 2138-2147.	7.0	71
133	Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.8	362
134	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. <i>Nature Genetics</i> , 2015, 47, 996-1002.	21.4	348
135	PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?. <i>Journal of Clinical Pathology</i> , 2015, 68, 12-17.	2.0	48
136	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	1.6	385
137	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. <i>Clinical Cancer Research</i> , 2015, 21, 3052-3060.	7.0	198
138	Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping. <i>Human Pathology</i> , 2015, 46, 1418-1426.	2.0	33
139	Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 326-342.	4.1	36
140	Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8035-8035.	1.6	24
141	Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9009-9009.	1.6	22
142	Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS9088-TPS9088.	1.6	5
143	Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. <i>Oncotarget</i> , 2015, 6, 24990-25002.	1.8	49
144	Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy. <i>Diabetes Care</i> , 2015, 38, e55-e57.	8.6	278

#	ARTICLE	IF	CITATIONS
145	Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. <i>Cancer Cell International</i> , 2014, 14, 4.	4.1	6
146	MEK targeting in N-RAS mutated metastatic melanoma. <i>Molecular Cancer</i> , 2014, 13, 45.	19.2	61
147	Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. <i>Clinical Cancer Research</i> , 2014, 20, 3328-3337.	7.0	33
148	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	1.6	2,015
149	Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9002-9002.	1.6	64
150	NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. <i>Oncotarget</i> , 2014, 5, 5209-5217.	1.8	3
151	Nivolumab plus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 122-133.	27.0	3,776
152	Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. <i>BMC Clinical Pathology</i> , 2013, 13, 3.	1.8	15
153	Advances in therapy for melanoma brain metastases. <i>Clinics in Dermatology</i> , 2013, 31, 264-281.	1.6	36
154	Radiation sensitivity and sensitization in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 928-930.	3.3	9
155	Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9012-9012.	1.6	20
156	Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. <i>PLoS ONE</i> , 2013, 8, e69748.	2.5	3
157	Advances in the systemic treatment of metastatic melanoma. <i>Oncology</i> , 2013, 27, 374-81.	0.5	3
158	Drug targets and predictive biomarkers in the management of metastatic melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 139.	0.7	3
159	Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. <i>Journal of Neurosurgery</i> , 2012, 117, 227-233.	1.6	296
160	Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. <i>Current Oncology Reports</i> , 2012, 14, 449-457.	4.0	56
161	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. <i>Nature Genetics</i> , 2012, 44, 1006-1014.	21.4	1,052
162	Immunotherapy for metastatic melanoma. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 725-734.	2.6	14

#	ARTICLE	IF	CITATIONS
163	Melanoma Brain Metastases: Is It Time to Reassess the Bias?. <i>Current Problems in Cancer</i> , 2011, 35, 200-210.	2.0	33
164	Molecular Alternations in Uveal Melanoma. <i>Current Problems in Cancer</i> , 2011, 35, 211-224.	2.0	9
165	In vitro studies of dasatinib, its targets and predictors of sensitivity. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 386-389.	3.3	12
166	A phase 2 trial of dasatinib in advanced melanoma. <i>Cancer</i> , 2011, 117, 2202-2208.	4.1	129
167	Plasma Markers for Identifying Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 2417-2425.	7.0	80
168	Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. <i>Journal of Translational Medicine</i> , 2010, 8, 67.	4.4	210
169	Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. <i>Breast Cancer Research</i> , 2010, 12, R66.	5.0	15
170	Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 6029-6039.	7.0	77
171	Ipilimumab: a promising immunotherapy for melanoma. <i>Oncology</i> , 2010, 24, 1280-8.	0.5	17
172	C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas. <i>Clinical Cancer Research</i> , 2009, 15, 5704-5713.	7.0	37
173	Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 3029-3036.	7.0	59
174	Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. <i>Clinical Cancer Research</i> , 2009, 15, 1076-1085.	7.0	38
175	Chemotherapy and biologic therapies for melanoma: do they work?. <i>Clinics in Dermatology</i> , 2009, 27, 614-625.	1.6	83
176	Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. <i>Laboratory Investigation</i> , 2008, 88, 962-972.	3.7	47
177	Apoptosis: a clinical perspective. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 959-959.	46.4	9
178	Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R35.	5.0	53
179	Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer. <i>Journal of Immunotherapy</i> , 2008, 31, 569-576.	2.4	44
180	Assessing Expression of Apoptotic Markers Using Large Cohort Tissue Microarrays. , 2008, 414, 83-93.		2

#	ARTICLE	IF	CITATIONS
181	Increased Expression of the E3 Ubiquitin Ligase RNF5 Is Associated with Decreased Survival in Breast Cancer. <i>Cancer Research</i> , 2007, 67, 8172-8179.	0.9	51
182	The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. <i>Journal of Translational Medicine</i> , 2007, 5, 6.	4.4	82
183	Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma. <i>Clinical Cancer Research</i> , 2006, 12, 3856-3863.	7.0	34
184	Association between pathways in regulatory networks. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , 2006, , .	0.5	0
185	Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease. <i>Cancer Research</i> , 2005, 65, 5578-5587.	0.9	73
186	Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4083-4089.	7.0	49
187	Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5188-5194.	7.0	85
188	Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma. <i>Cancer Research</i> , 2004, 64, 8773-8777.	0.9	75
189	Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis. <i>Clinical Cancer Research</i> , 2004, 10, 173-177.	7.0	99
190	Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome. <i>Cancer Research</i> , 2004, 64, 8767-8772.	0.9	60
191	cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. <i>Laboratory Investigation</i> , 2004, 84, 320-331.	3.7	66
192	?B-crystallin as a marker of lymph node involvement in breast carcinoma. <i>Cancer</i> , 2004, 100, 2543-2548.	4.1	65
193	Her2/neu is not a commonly expressed therapeutic target in melanoma - a large cohort tissue microarray study. <i>Melanoma Research</i> , 2004, 14, 207-210.	1.2	39